Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases

 Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases

Takeda Signs a License Agreement with Goldfinch Bio for its GFB-024 to Treat Rare and Metabolic Kidney Diseases

Shots:

  • Goldfinch to be responsible for all WW development & commercialization activities of GFB-024. Takeda to get an option to sub-license rights of GFB-024, prior to the initiation of the pivotal studies in Japan
  • Goldfinch to utilize its biology platform and Kidney Genome AtlasTM to develop GFB-024. Additionally, its GFB-887 (TRPC5 inhibitor) is being evaluated in P-I study for focal segmental glomerulosclerosis
  • GFB-024 is a CB1 inhibitor with its preclinical data supporting the inhibition of CB1 signaling as a novel treatment of diabetic nephropathy and obesity-related glomerulopathies with its expected initiation of P-I study in H2’20

Click here to­ read full press release/ article | Ref: Goldfinch Bio | Image: Takeda

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post